explore -WSS

explore

author：entertainment 2025-09-14 14:43:49 - browse：39726

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： In Memoriam: Notable people who died in 2023

WSS

Using force crossed my mind when examining a defiant young patient

ChatGPT in medicine: STAT answers readers' burning questions

Childhood vaccination ad campaign launches in the U.K.

DIEP, the 'gold standard' of breast reconstruction, is under threat

Are embryos people? Reproductive medicine's future depends on the answer

Trump demands the U.S. pay no more for drugs than other countries … again

knowledge

explore

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Activists slam private health insurers over coverage restrictions

How one medical school became remarkably diverse

Ohio train derailment: Experts on toxic chemical risks

Medicare details structure of new drug price negotiation program

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wildfire smoke exposes gaps in outdoor worker protections

In Memoriam: Notable people who died in 2023

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

entertainment

Using force crossed my mind when examining a defiant young patient

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

CDC advisory group OKs chikungunya vaccine

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare details structure of new drug price negotiation program

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

entertainment

knowledge

entertainment

hotspot